Company News

Cold chain technology deal

GE Healthcare has expanded its capacity for industralising cell therapies with the acquisition of Asymptote Ltd, a UK consultancy with technology for simplifying the freezing of cells intended as therapies, and thawing them before their use in patients.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

FDA says more data needed for baricitinib

The US Food and Drug Administration has turned back an application from Eli Lilly and Company for baricitinib, a candidate treatment for rheumatoid arthritis, saying that more data is needed to determine the most appropriate doses of the drug for use in patients.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Offer for Germany’s leading generic producer

The management of Stada Arzneimittel AG, Germany’s leading generics producer, has accepted a €4.1 billion offer for the company from two private equity firms, Bain Capital Private Equity LP of Boston Massachusetts, US and Cinven Partners LLP of London, UK.

Location

Germany

Roche says Alecensa more effective than rival drug in lung cancer

Roche said that its kinase inhibitor Alecensa (alectinib) has produced better results in a Phase 3 trial of patients with a specific type of lung cancer than a rival treatment marketed by Pfizer Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

David Meeker to step down from Genzyme

David Meeker, who has led Genzyme since Sanofi SA took over the US specialty pharma company in 2011, is to step down at the end of June to make way for Bill Sibold, head of Genzyme’s multiple sclerosis, oncology and immunology businesses.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Positive data for HDAC inhibitor - Medivir

Sweden-based Medivir AB has reported positive Phase 2 data for a recently acquired histone deacetylase (HDAC) inhibitor in a trial of patients with early-stage cutaneous T cell lymphoma (CTCL), a haematologic cancer that presents in the skin.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden

Nanobiotix raises €25.1 million in private placement

Nanobiotix SA, which is developing technology for enhancing radiotherapy treatments, has raised €25.1 million in a private share placement to finance its portfolio and the expected European market launch of its lead product NBTXR3.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Symetis gains access to US market

Switzerland-based Symetis GmbH has made a major step onto the US medical device market after agreeing to be acquired by Boston Scientific Corp. The deal, announced on 30 March, consolidates the two companies’ technologies for treating valvular heart disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Seed funding for Imperial College spin-out

Cardian Ltd, a new spin-out from Imperial College London, has received £1.5 million in seed funding to commercialise a device for monitoring patients with heart failure and help physicians manage their care. The device does not need batteries or a power line.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Abzena proposes private share placement

UK-based Abzena Plc is proposing to raise about £25 million through a private share placement to finance the expansion of its technology services to companies in the US and Europe. The company is listed on the AIM market, which is part of the London Stock Exchange.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content